3 results
Approved WMOCompleted
Part 1 (open-label, 8 week): safety and tolerability of eltrombopag, optimal dose escalation scheme for use in Part 2, PK.Part 2: Primary: the reduction in the number of clinically relevant thrombocytopenic events (*Grade 3 hemorrhagic adverse…
Approved WMOCompleted
To study whether an existing sensor device containing motion/orientation sensors (SMM; Senior Mobility Monitor) can be used to observe progress of labour.
Approved WMOCompleted
The objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response and blood counts and can be use as front-line therapy for SAA treatment.